Receptor-binding domain-based subunit vaccines against MERS-CoV
- 1 April 2015
- journal article
- research article
- Published by Elsevier in Virus Research
- Vol. 202, 151-159
- https://doi.org/10.1016/j.virusres.2014.11.013
Abstract
No abstract availableKeywords
Funding Information
- NIH (R21AI109094)
This publication has 80 references indexed in Scilit:
- Engineering a Replication-Competent, Propagation-Defective Middle East Respiratory Syndrome Coronavirus as a Vaccine CandidatemBio, 2013
- Adaptive evolution of bat dipeptidyl peptidase 4 (dpp4): implications for the origin and emergence of Middle East respiratory syndrome coronavirusVirology Journal, 2013
- Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirusProceedings of the National Academy of Sciences, 2013
- Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4Cell Research, 2013
- Human Betacoronavirus 2c EMC/2012–related Viruses in Bats, Ghana and EuropeEmerging Infectious Diseases, 2013
- An Interaction between the Nucleocapsid Protein and a Component of the Replicase-Transcriptase Complex Is Crucial for the Infectivity of Coronavirus Genomic RNAJournal of Virology, 2010
- A 219-mer CHO-Expressing Receptor-Binding Domain of SARS-CoV S Protein Induces Potent Immune Responses and Protective ImmunityViral Immunology, 2010
- Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunityVirology, 2009
- Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cellsBiochemical and Biophysical Research Communications, 2009
- The spike protein of SARS-CoV — a target for vaccine and therapeutic developmentNature Reviews Microbiology, 2009